The Brazil Digital PCR Market was valued at $187.1 Million in 2024 and projected to reach to $261.6 Million by 2029, representing a compound annual growth rate of 6.9%. Brazil's digital PCR market is poised for sustained expansion as healthcare providers increasingly recognize the value of advanced molecular diagnostics in clinical decision-making.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Brazil's digital PCR market is valued at USD 187.1 million in 2024, with strong growth trajectory positioning it as a key market in Latin America for molecular diagnostics.
The Brazilian market is expanding at a CAGR of 6.9% through 2029, outpacing many emerging markets and reflecting increasing healthcare infrastructure investments and diagnostic adoption.
Rising demand for precision medicine and personalized treatment approaches in Brazil is driving healthcare providers to adopt advanced digital PCR technologies for accurate molecular diagnostics.
Growing investments in Brazil's healthcare sector, coupled with expanding laboratory networks and research institutions, are accelerating the deployment of digital PCR systems across diagnostic centers.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | DPCR (Offering) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 8.1% from 2024 to 2029 |
| Largest Segment | QPCR (Offering) |
| Market Size Base Year (Billions) | ~USD 10.03 (2024) |
| Revenue Forecast (Billions) | ~USD 14.8 (2029) |
| Segments Covered | Offering, Type, Application, End User |
4 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 29.4 | 26.1 | 27.1 | 28.2 | 29.6 | 31.2 | 33.1 | 35.5 | 5.6 |
| CROS AND CDMOS | 17.6 | 15.6 | 16.4 | 17.4 | 18.5 | 19.8 | 21.3 | 23.2 | 7.2 |
| FORENSIC LABORATORIES | 13.1 | 11.5 | 11.9 | 12.3 | 12.8 | 13.4 | 14.2 | 15.1 | 5 |
| HOSPITALS AND DIAGNOSTIC LABORATORIES | 95.6 | 91 | 96.5 | 102.8 | 110.1 | 118.7 | 129 | 141.4 | 7.9 |
| OTHER END USERS | 11.34 | 10.25 | 10.48 | 10.76 | 11.1 | 11.52 | 12.04 | 12.69 | 3.9 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 24.3 | 23.8 | 24.8 | 26 | 27.5 | 29.2 | 31.2 | 33.7 | 6.3 |
| TOTAL | 191.3 | 178.3 | 187.1 | 197.4 | 209.5 | 223.8 | 240.8 | 261.6 | 6.9 |
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 3.5 | 3.2 | 3.4 | 3.7 | 4 | 4.3 | 4.7 | 5.1 | 8.4 |
| CROS AND CDMOS | 2.1 | 2 | 2.2 | 2.4 | 2.6 | 2.8 | 3.1 | 3.5 | 9.8 |
| FORENSIC LABORATORIES | 2 | 1.8 | 1.9 | 2 | 2.2 | 2.3 | 2.5 | 2.8 | 7.8 |
| HOSPITALS AND DIAGNOSTIC LABORATORIES | 12.5 | 11.3 | 12.3 | 13.4 | 14.7 | 16.2 | 18 | 20.2 | 10.6 |
| OTHER END USERS | 1 | 1 | 1 | 1 | 1.1 | 1.1 | 1.2 | 1.2 | 4.5 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 3.1 | 2.8 | 3 | 3.2 | 3.4 | 3.7 | 4.1 | 4.5 | 8.8 |
| TOTAL | 24.2 | 22 | 23.7 | 25.7 | 27.9 | 30.5 | 33.6 | 37.4 | 9.5 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| NANOSTRING TECHNOLOGIES, INC | United States | Private Company | nCounter instruments and consumables (Pro, FLEX, SPRINT, CodeSets, panels, reagents),GeoMx DSP and spatial biology solutions,Prosigna IVD and clinical assays, |
| AFFYMETRIX INC | United States | Private Company | GeneChip gene expression and genotyping arrays,CytoScan and OncoScan cytogenetics and oncology products,eBioscience antibodies, flow cytometry, and immunoassays, |
| DECODE GENETICS | Iceland | Private Company | Internal discovery for Amgen pipeline,External research collaborations and data services,Licensing of genetic discoveries and IP, |
| DENVILLE SCIENTIFIC | United States | Private Company | Pipetting systems and tips,Centrifuge tubes, plates, and sample storage,Molecular biology equipment and thermal cyclers, |
| ROSETTA GENOMICS | Israel | Public Company | RosettaGX Cancer Origin & mi-LUNG,RosettaGX Reveal (thyroid FNA),mi-KIDNEY and other microRNA classifiers, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and related solutions),Life Sciences (research and analytical instruments, genomics),Diagnostics (clinical instruments, consumables, software), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| MERCK KGAA | Germany | Public Company | Life Science (tools, reagents, bioprocessing, CDMO),Healthcare (prescription drugs, biopharmaceuticals),Electronics (semiconductor and display materials, equipment), |
| QIAGEN N.V. | Netherlands | Public Company | Sample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, SRH, transplant, viral load),PCR and enzymes (qPCR, digital PCR, RT-PCR, configured solutions), |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics systems, reagents, and quality controls,Life Science instruments and reagents,Other and services (software, support, education, ancillary), |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| TAKARA BIO INC. | Japan | Private Company | Genetic and cellular research reagents,Instruments and cellular analysis devices,COVID-19 and other in vitro diagnostics, |
| BECTON, DICKINSON, AND COMPANY | United States | Public Company | Medical Essentials (syringes, needles, catheters, sharps, vascular access),Connected Care (infusion, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, related solutions), |
| ABBOTT LABORATORIES | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| MERIDIAN BIOSCIENCE | United States | Private Company | Molecular reagents (PCR/RT-PCR enzymes, dNTPs, buffers, ready-to-use solutions, qPCR controls),Immunoassay raw materials (antigens, antibodies, interference blockers),Custom antibody and protein manufacturing services, |
| BIOMÉRIEUX | France | Public Company | Microbiology (culture media, BACT/ALERT VIRTUO, TEMPO, CHEMUNEX, BIOBALL, ENDONEXT),ID/AST Systems (VITEK 2, VITEK MS, VITEK REVEAL, API RANGE, ETEST, RAPIDEC CARBA NP),Molecular & Syndromic PCR (BIOFIRE, BIOFIRE SPOTFIRE, ARGENE, EMAG, NUCLISENS), |
| EPPENDORF AG | Germany | Private Company | Liquid handling (pipettes, dispensers, automated systems),Separation & instrumentation (centrifuges, PCR cyclers, ULT freezers),Consumables (tubes, tips, plates, single-use bioreactors), |
NanoString Technologies, Inc. is a U.S.-based private company founded in 2003 with 550 employees that develops molecular analysis platforms for life science research.
Affymetrix Inc. is a U.S. private company founded in 1991 with 1,150 employees that develops and manufactures molecular analysis tools and genomic platforms.
Decode Genetics is an Icelandic private company founded in 1996 with 331 employees engaged in genomic research and genetic analysis.
Denville Scientific is a U.S.-based private company founded in 1979 specializing in laboratory equipment and scientific supplies.
Rosetta Genomics is an Israeli public company founded in 2000 with 86 employees focused on genomic and molecular diagnostics.
Danaher Corporation is a U.S.-based public company founded in 1969 with 59,000 employees operating a diversified conglomerate with significant life sciences and diagnostics divisions.
Thermo Fisher Scientific Inc. is a U.S.-based public company founded in 1956 with 125,000 employees providing laboratory equipment, reagents, and analytical instruments worldwide.
Merck KGaA is a German public company founded in 1668 with 59,077 employees operating in pharmaceuticals, life sciences, and performance materials.
QIAGEN N.V. is a Netherlands-based public company founded in 1984 with 5,500 employees specializing in molecular diagnostics and life sciences sample preparation.
Bio-Rad Laboratories, Inc. is a U.S.-based public company founded in 1952 with 7,450 employees manufacturing clinical diagnostics and life science research products.
Agilent Technologies, Inc. is a U.S.-based public company founded in 1999 with 18,000 employees providing analytical instruments and life sciences solutions.
Takara Bio Inc. is a Japanese private company founded in 2002 with 1,779 employees specializing in molecular biology reagents and biotechnology products.
Becton, Dickinson, and Company is a U.S.-based public company founded in 1897 with 72,000 employees manufacturing medical devices, diagnostics, and laboratory equipment.
Abbott Laboratories is a U.S.-based public company founded in 1888 with 115,000 employees operating in diagnostics, pharmaceuticals, nutritional products, and medical devices.
Meridian Bioscience is a U.S.-based private company founded in 1976 with 704 employees developing and manufacturing diagnostic products and reagents.
bioMérieux is a French public company founded in 1963 with 14,894 employees specializing in in vitro diagnostics and microbiology testing solutions.
Eppendorf AG is a German private company founded in 1945 with 4,358 employees manufacturing laboratory equipment and consumables for life sciences research.
Brazil's digital PCR market was valued at USD 187.1 million in 2024 and is expected to grow to USD 261.6 million by 2029.
Brazil's digital PCR market is projected to grow at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2029.
Brazil's digital PCR market growth is driven by increasing demand for precision medicine, expanding clinical applications in infectious disease and oncology, and growing investments in healthcare infrastructure.
Brazil's digital PCR adoption is expanding across both public and private laboratory settings, including clinical diagnostics, research institutions, and pharmaceutical companies.
Brazil represents a significant portion of the Latin American digital PCR market, with steady growth positioning it as a key regional contributor to market expansion.
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global digital PCR (dPCR) and real-time PCR (qPCR) market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the digital PCR (dPCR) and real-time PCR (qPCR) market. The secondary sources used for this study include World Bank, GLOBOCAN, World Health Organization (WHO), Eurostat, International Trade Administration, National Human Genome Research Institute (NHGRI, US), National Institutes of Health (NIH) (US), Institute for Health Metrics and Evaluation (US), US Food and Drug Administration (US FDA), Health Canada, European Medicines Agency (UK), Centers for Disease Control and Prevention (CDC), National Cancer Institute (NCI), European Medicines Agency (EMA), German Cancer Research Center, NHS (UK), Medicines and Healthcare Products Regulatory Agency (UK), Pharmaceuticals and Medical Devices Agency (Japan), Beijing Institute of Genomics (China), Ministry of Science & Technology (India), Ministry of Food and Drug Safety (South Korea), BioPlan Associates, Eurostat, and Factiva, research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Extensive primary research was conducted after acquiring basic knowledge about the global digital PCR (dPCR) and real-time PCR (qPCR) market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, Middle East and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the digital PCR (dPCR) and real-time PCR (qPCR) market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

To know about the assumptions considered for the study, Request for Free Sample Report
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Polymerase chain reaction (PCR) is a well-established technique used for the in vitro amplification of a given nucleotide (such as DNA). Digital polymerase chain reaction (digital PCR or dPCR) is a third-generation polymerase chain reaction technique that is used to clonally amplify and directly quantify nucleic acid strands, including DNA, cDNA, or RNA. Similarly, quantitative/real-time PCR (qPCR) is a well-established PCR technique that is widely utilized in DNA identification, amplification, and quantification. It involves the real-time analysis of reaction mixtures with the aid of fluorescent markers that are specific to either the end product or the reactant.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Digital PCR Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report